RLF — RELIEF THERAPEUTICS Holding SA Income Statement
0.000.00%
- CH₣29.53m
- CH₣16.60m
- CH₣8.42m
- 28
- 26
- 27
- 14
Annual income statement for RELIEF THERAPEUTICS Holding SA, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 3.32 | 6.08 | 6.03 | 8.42 |
Cost of Revenue | |||||
Gross Profit | — | 2.57 | 4.83 | 4.3 | 5.84 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5.7 | 37.6 | 58.1 | 117 | 27.6 |
Operating Profit | -5.7 | -34.3 | -52 | -111 | -19.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.26 | -35.5 | -54.3 | -112 | -19.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.83 | -34.7 | -50.8 | -98.2 | -17.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.83 | -34.7 | -50.8 | -98.2 | -17.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.83 | -34.7 | -50.8 | -98.2 | -17.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.87 | -3.81 | -3.18 | -3.3 | -0.757 |
Dividends per Share |